

## Diagnostika uroteliálního karcinomu močového měchýře pomocí fluorescenční endoskopie

DIRK ZAAK, ALEXANDER KARL, RUTH KNÜCHEL\*, HERBERT STEPP†, ARNDT HARTMANN‡, OLIVER REICH, ALEXANDER BACHMANN, MICHAEL SIEBELS, GRALF POPKEN¶ a CHRISTIAN STIEF

Department of Urology and †Laser Research Laboratory, Klinikum Großhadern, Ludwig-Maximilians-University of Munich, \*Institute of Pathology, University of Aachen, ‡Institute of Pathology, University of Regensburg, and ¶Department of Urology, Klinikum Berlin-Buch, Germany

### LITERATURA

- 1 Kurth KH. Natural history and prognosis of untreated and treated superficial bladder cancer. In Pagano F, Fair WR eds, *Superficial Bladder Cancer*. Oxford: Isis Medical Media, 1997: 42–56
- 2 Schellhammer PF. Immediate adjuvant intravesical chemotherapy after transurethral resection of the bladder. *Current Opinion Urol* 1998; **8**: 407–9
- 3 Witjes JA. Bladder carcinoma in situ in 2003. State of the art. *Eur Urol* 2004; **45**: 142–6
- 4 Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: Why? *Eur Urol* 2004; **45**: 539–46
- 5 Whitmore WF Jr, Bush IM. Ultraviolet cystoscopy in patients with bladder cancer. *Trans Am Assoc GenitourinSurg* 1965; **57**: 149–55
- 6 Vicente J, Chechile G, Algaba F. Value of *in vivo* mucosa-staining test with methylene blue in the diagnosis of pretumoral and tumoral lesions of the bladder. *Eur Urol* 1987; **13**: 15–6
- 7 Zimmern PE, Laub D, Leach GE. Fluorescein angiography of the bladder: technique and relevance to bladder cancer and interstitial cystitis patients. *J Urol* 1995; **154**: 62–5
- 8 Jocham D, Baumgartner R, Fuchs N, Lenz H, Stepp H, Unsöld E. Fluorescence diagnosis of porphyrin-marked urothelial tumors. Status of experimental development. *Urologe A* 1989; **28**: 59–64
- 9 Steinbach P, Weingandt H, Baumgartner R, Kriegmair M, Hofstädter F, Knüchel R. Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. *Photochem Photobiol* 1995; **62**: 887–95
- 10 Ickowicz Schwartz D, Gozlan Y, Greenbaum L, Babushkina T, Katcoff DJ, Malik Z. Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. *Br J Cancer* 2004; **90**: 1833–41
- 11 Greenbaum L, Katcoff DJ, Dou H, Gozlan Y, Malik Z. A porphobilinogen deaminase (PBGD) Ran-binding protein interaction is implicated in nuclear trafficking of PBGD in differentiating glioma cells. *Oncogene* 2003; **22**: 5221–8
- 12 Krieg RC, Fickweiler S, Wolfbeiss OS, Kneuchel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. *Photochem Photobiol* 2000; **72**: 226–33
- 13 Zaak D, Kriegmair M, Stepp H *et al*. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid – results of 1012 fluorescence endoscopies. *Urology* 2001; **57**: 690–4
- 14 Uehlinger P, Zellweger M, Wagnières G, Juillerat-Jeanneret L, van den Bergh H, Lange N. 5-aminolevulinic acid and its derivatives. *J Photochem Photobiol* 2000; **54**: 72–80
- 15 Lange N, Jichlinski P, Zellweger M *et al*. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX. a pilot study. *Br J Cancer* 1999; **80**: 185–93
- 16 Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of Hypericin; a compound with a broad spectrum of biological activities. *Med Res Rev* 1995; **15**: 111–9
- 17 Schemp CM, Muller K, Winghofer B, Schulte-Monting J, Simon JC. Single dose and steady state administration of *Hypericum perforatum* extract (St John's wort) does not influence skin sensitivity to UV radiation, visible light and solarsimulated radiation. *Arch Dermatol* 2001; **137**: 512–3
- 18 Yamazaki T, Ohta N, Yamazaki I, Song PS. Excited state properties of hypericin: electronic spectra and fluorescence decay kinetics. *J Phys Chem* 1993; **97**: 7870–5
- 19 Kamuhabwa A, Cosserat-Gerardin I, Didelon J *et al*.

- Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. *Int J Cancer* 2002; **97**: 126–32
- 20 Jichlinski P, Guillou L, Karlsen SJ *et al*. Hexyl aminolevulinic acid fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer – a multicenter study. *J Urol* 2003; **170**: 226–9
- 21 D'Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. *Eur Urol* 2002; **42**: 417–25
- 22 Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. *J Urol* 1996; **155**: 105–9
- 23 Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. *J Endourol* 1999; **13**: 117–21
- 24 König F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced 5-aminolevulinic acid. *BJU Int* 1999; **83**: 129–35
- 25 Zaak D, Hungerhuber E, Schneede P *et al*. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. *Cancer* 2002; **95**: 1234–8
- 26 Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. *World Health Organization of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs*. Lyon: IARC Press, 2004
- 27 Witjes JA, Kiemeneij LALM, Verbeek ALM, Heijbroeck RP, DeBruyne FMJ. Random bladder biopsies and the risk of recurrent superficial bladder cancer – a prospective study in 1026 patients. *World J Urol* 1992; **10**: 231–4
- 28 Schmidbauer J, Witjes F, Schmeller N *et al*. Improved detection of urothelial carcinoma in situ with hexaminolevulinic acid fluorescence cystoscopy. *J Urol* 2004; **171**: 135–8
- 29 D'Hallewin MA, Kamuhabwa AT, Roskams De Witte P, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. *BJU Int* 2002; **89**: 760–3
- 30 Zaak D, Frimberger D, Stepp H *et al*. Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. *J Urol* 2001; **166**: 1665–9
- 31 Hartmann A, Rösner U, Schlake G *et al*. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. *Laboratory Invest* 2000; **80**: 709–18
- 32 Obermann EC, Junker K, Stoehr R *et al*. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. *J Pathol* 2003; **199**: 50–7
- 33 Filbeck T, Roessler W, Knüchel R, Straub M, Kiel HJ, Wieland WF. 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. *Urology* 1999; **53**: 77–81
- 34 Grimbergen MCM, Van Swol CFP, Jonges TGN *et al*. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. *Eur Urol* 2003; **44**: 51–6
- 35 D'Hallewin MA, De Witte P, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. *J Urol* 2000; **164**: 349–51
- 36 Riedl CR, Daniltschenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. *J Urol* 2001; **165**: 1121–3
- 37 Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? *Urology* 2002; **60**: 1025–8
- 38 Kriegmair M, Zaak D, Rothenberger KH *et al*. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. *J Urol* 2002; **168**: 475–8
- 39 Filbeck T, Pichlmeier U, Knüchel R, Wieland WF, Rößler W. Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis. Results of a 5-year study. *Urologe A* 2003; **42**: 1366–73
- 40 Filbeck T, Wimmershoff MB, Pichlmeier U *et al*. No generalized skin phototoxicity after application of 5-aminolevulinic acid for fluorescence diagnosis of superficial bladder cancer. *Urol Int* 2000; **64**: 126–8
- 41 Popken G, Schütze-Seeman W, Seiler KU, Birkel M, Wetterauer U. Intravesical administration of 5-

- aminolevulinic acid (5-ALA)  
Safety and pharmacokinetics of  
5-ALA and its metabolite  
protoporphyrin IX. *Eur J Clin  
Pharmacol* 2000; **56**: 241–6
- 42 Stenzl A, Hörtl L, Bartsch G.  
Fluorescence assisted  
transurethral resection of  
bladder tumours: is it cost  
effective? *Eur Urol* 2001; **39**: 31

Korespondence:  
Dirk Zaak,  
Department of Urology,  
Klinikum Großhadern,  
D-81377 Munich, Germany.  
e-mail: [Dirk.Zaak@med.uni-  
muenchen.de](mailto:Dirk.Zaak@med.uni-muenchen.de)

Zkratky:  
**ALA**, 5-aminolaevulinic acid; **HAL**,  
hexyl-ALA ester; **TURBT**,  
transurethral resection of bladder  
tumour; **Cis**, carcinoma *in situ*;  
**WLE**, white-light endoscopy; **PDD**,  
photodynamic diagnosis; **PPIX**,  
protoporphyrin IX